Study Says MitraClip® Offers Mitral Regurgitation Solution to Sickest Patients

Last time we reported on Abbott’s MitraClip® device we were covering the news that it was effective even in patients with severe mitral regurgitation. Now the company is telling us the story from its early commercialisation of the system in the U.S.

Background

Abbott’s MitraClip repairs the mitral valve without the need for an invasive surgical procedure, making it an option for people not able to tolerate such an intervention. The device is delivered to the heart through the femoral vein, a blood vessel in the leg, and once implanted, allows the heart to pump blood more efficiently, thereby relieving symptoms and improving people’s quality of life.

89 year old Betty Vaughn of Golden Valley, Minn., was diagnosed with degenerative mitral regurgitation (DMR)three years ago. Cardiologist Paul Sorajja, M.D., from Abbott Northwestern Hospital in Minneapolis, performed a transcatheter mitral valve repair (TMVR) procedure using Abbott’s MitraClip® in October 2014. Now, just months after the procedure, Betty Vaughn has resumed many of the activities she loves, like working in the yard and playing cards with friends.

Abbott has seen results of its MitraClip implantations presented at the American College of Cardiology’s (ACC) 64th Annual Scientific Session & Expo by Dr Sorajja, lead investigator in its study. Results were presented from a transcatheter valve therapy (TVT) registry formed from a partnership with the Society of Thoracic Surgeons (STS) and ACC. Researchers evaluated data from 564 people with TMVR who were treated with MitraClip following FDA approval of the device in October 2013 through August 2014. The data continue to support the use of MitraClip, with successful treatment for 93 percent of people in the study. The treated group’s median age was 83 years-old, and they were not candidates for surgery because they were too frail or had other complicating factors.

Physician comments

“The results of this MitraClip study are very favorable and consistent with the results we saw in studies prior to the therapy’s U.S. approval,” Dr. Sorajja said. “The results show clinically meaningful reduction in the severity of mitral regurgitation and improvement in the overall health of very sick people with prohibitive risk DMR who have no other meaningful options to improve their lives.”

Patient comments 

“[My doctor] said I would feel better, and I did,” Vaughn said. “That’s the difference. I’m living now. I’m doing much better.”

Source: PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *